INmune Bio CSO exercises 7,211 warrants
INmune Bio, Inc. Chief Scientific Officer Mark William Lowdell exercised common stock purchase warrants to acquire 7,211 shares of Common Stock at an exercise price of $1.40 per share.
Rhea-AI Filing Summary
INmune Bio, Inc. Chief Scientific Officer Mark William Lowdell exercised common stock purchase warrants to acquire 7,211 shares of Common Stock at an exercise price of $1.40 per share. This increased his directly held stake to 1,518,017 Common shares.
The exercise was part of a warrant inducement arrangement tied to April 2024 Warrants. Lowdell agreed to exercise 50% of his April 2024 Warrants for cash, while the company extended the maturity date of the remaining 50% of those warrants from June 30, 2026 to December 31, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
7,211 shares exercised/converted
Exercise
2 txns
Insider
Lowdell Mark William
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Common Stock Purchase Warrant | 7,211 | $0.125 | $901.38 |
| Exercise | Common Stock | 7,211 | $1.40 | $10K |
Holdings After Transaction:
Common Stock Purchase Warrant — 7,212 contracts (Direct);
Common Stock — 1,518,017 shares (Direct)
Footnotes (1)
- F1. Represents 7,211 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 7,211 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 7,211 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.
Key Figures
Shares acquired via exercise: 7,211 shares
Exercise price: $1.40 per share
Shares held after transaction: 1,518,017 shares
+3 more
6 metrics
Shares acquired via exercise
7,211 shares
Common Stock from April 2024 Warrants exercised on July 2, 2026
Exercise price
$1.40 per share
Cash exercise price for 7,211 April 2024 Warrants
Shares held after transaction
1,518,017 shares
Total Common Stock directly owned by Lowdell following exercise
Warrants exercised
50% of April 2024 Warrants
Portion of Lowdell’s April 2024 Warrants exercised for cash
Remaining warrant maturity extension
to December 31, 2027
New maturity date for unexercised April 2024 Warrants, from June 30, 2026
Warrant exercise transaction price
$0.1250 per warrant
Reported transaction price per Common Stock Purchase Warrant
Key Terms
Common Stock Purchase Warrant, warrant inducement offer letter agreement, April 2024 Warrants, exercise price, +1 more
5 terms
Common Stock Purchase Warrant financial
"Represents 7,211 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
warrant inducement offer letter agreement financial
"entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter")."
April 2024 Warrants financial
"as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement"
exercise price financial
"agreed to purchase 7,211 shares of common stock at a reduced exercise price of $1.40"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
maturity date financial
"extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50%"
The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did INmune Bio (INMB) executive Mark Lowdell report in this Form 4?
Mark William Lowdell, Chief Scientific Officer of INmune Bio, reported exercising common stock purchase warrants to acquire 7,211 shares of Common Stock at $1.40 per share, increasing his directly held position to 1,518,017 shares following the transaction.
What were the terms of the INmune Bio (INMB) warrant exercise reported by Mark Lowdell?
Lowdell exercised 7,211 April 2024 Warrants for cash at a reduced exercise price of $1.40 per share. These warrants converted into 7,211 shares of Common Stock under a warrant inducement offer letter agreement with INmune Bio, as detailed in the Form 4 footnote.
How did the INmune Bio (INMB) warrant inducement affect remaining April 2024 Warrants?
Under the inducement agreement, Lowdell exercised 50% of his April 2024 Warrants, while INmune Bio extended the maturity date of his remaining 50% April 2024 Warrants from June 30, 2026 to December 31, 2027, lengthening the time they can potentially be exercised.
Was the INmune Bio (INMB) transaction an open-market buy or a warrant exercise?
The transaction was a warrant exercise, not an open-market share purchase. Lowdell exercised 7,211 common stock purchase warrants for cash, converting them into 7,211 shares of Common Stock at a $1.40 exercise price pursuant to an inducement letter agreement with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
